Abstract
Salinomycin, traditionally used as an anti-coccidial drug, has recently been shown to possess anti-cancer and anti-cancer stem cell (CSC) effects, as well as activities to overcome multi-drug resistance based on studies using human cancer cell lines, xenograft mice, and in case reports involving cancer patients in pilot clinical trials. Therefore, salinomycin may be considered as a promising novel anti-cancer agent despite its largely unknown mechanism of action.
This review summarizes the pharmacologic effects of salinomycin and presents possible mechanisms by which salinomycin exerts its anti-tumorigenic activities. Recent advances and potential complications that might limit the utilization of salinomycin as an anti-cancer and anti-CSC agent are also presented and discussed.
Keywords: Salinomycin, cancer stem cell, toxicity, drug.
Current Medicinal Chemistry
Title:Salinomycin: A Novel Anti-Cancer Agent with Known Anti-Coccidial Activities
Volume: 20 Issue: 33
Author(s): Shuang Zhou, Fengfei Wang, Eric T. Wong, Ekokobe Fonkem, Tze-Chen Hsieh, Joseph M. Wu and Erxi Wu
Affiliation:
Keywords: Salinomycin, cancer stem cell, toxicity, drug.
Abstract: Salinomycin, traditionally used as an anti-coccidial drug, has recently been shown to possess anti-cancer and anti-cancer stem cell (CSC) effects, as well as activities to overcome multi-drug resistance based on studies using human cancer cell lines, xenograft mice, and in case reports involving cancer patients in pilot clinical trials. Therefore, salinomycin may be considered as a promising novel anti-cancer agent despite its largely unknown mechanism of action.
This review summarizes the pharmacologic effects of salinomycin and presents possible mechanisms by which salinomycin exerts its anti-tumorigenic activities. Recent advances and potential complications that might limit the utilization of salinomycin as an anti-cancer and anti-CSC agent are also presented and discussed.
Export Options
About this article
Cite this article as:
Zhou Shuang, Wang Fengfei, Wong T. Eric, Fonkem Ekokobe, Hsieh Tze-Chen, Wu M. Joseph and Wu Erxi, Salinomycin: A Novel Anti-Cancer Agent with Known Anti-Coccidial Activities, Current Medicinal Chemistry 2013; 20 (33) . https://dx.doi.org/10.2174/15672050113109990199
DOI https://dx.doi.org/10.2174/15672050113109990199 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the Treatment of Chronic Inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Role of EGFR Monoclonal Antibodies in the Management of Non–small Cell Lung Cancer
Current Cancer Drug Targets Polymer Nanoparticles - A Novel Strategy for Administration of Paclitaxel in Cancer Chemotherapy
Current Medicinal Chemistry The Association between NADPH Oxidase 2 (NOX2) and Drug Resistance in Cancer
Current Cancer Drug Targets Natural Endoperoxides as Drug Lead Compounds
Current Medicinal Chemistry MicroRNAs in Prostate Cancer Following Radiotherapy: Towards Predicting Response to Radiation Treatment
Current Medicinal Chemistry Targeted Enzyme Prodrug Therapies
Mini-Reviews in Medicinal Chemistry New Era on Combining Both Imaging and Drug Delivery to Treat Cancer
Current Pharmaceutical Biotechnology Role of CHK2 Inhibitors in the Cellular Responses to Ionizing Radiation
Mini-Reviews in Medicinal Chemistry Editorial [Hot Topic: Nitric Oxide: Implications for the Etiology & Treatment of Central Nervous System Disorders (Guest Editor: Giuseppe Di Giovanni)]
CNS & Neurological Disorders - Drug Targets Novel Marine-Derived Anti-Cancer Agents
Current Pharmaceutical Design Breast Cancer Resistance Protein: A Potential Therapeutic Target for Cancer
Current Drug Targets Anticancer Mechanisms of Berberine: A Good Choice for Glioblastoma Multiforme Therapy
Current Medicinal Chemistry Nutraceuticals and "Repurposed" Drugs of Phytochemical Origin in Prevention and Interception of Chronic Degenerative Diseases and Cancer
Current Medicinal Chemistry Targeting Mutant-p53 for Cancer Treatment: Are We There Yet?
Current Molecular Pharmacology Vandetanib, A Dual Inhibitor of VEGFR and EGFR Tyrosine Kinase Activity
Current Cancer Therapy Reviews EGFR-Targeting Monoclonal Antibodies in Head and Neck Cancer
Current Cancer Drug Targets The Role of CDK20 Protein in Carcinogenesis
Current Drug Targets Targeting Brain Tumors with Nanomedicines: Overcoming Blood Brain Barrier Challenges
Current Clinical Pharmacology Antibody-based Radiopharmaceuticals as Theranostic Agents: An Overview
Current Medicinal Chemistry T Cell Costimulatory and Inhibitory Receptors as Therapeutic Targets for Inducing Anti-Tumor Immunity
Current Cancer Drug Targets